Ovarian Cancer’s PARP Inhibitor Gold Rush Is Over — What Comes Next Will Separate the Winners From the Wreckage
PARP inhibitors reshaped ovarian cancer treatment, but with olaparib holding 38% market share and biomarker limits exposed, the next...
Ovarian Cancer